Felix Morris, MD
Sleep Medicine · Florence, ALNPI 1689613739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 793 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 793 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$1K
- Harmony Biosciences LLC$893
- Insmed, Inc.$782
- plus $5K from 33 others
Across 1 payment — averaging $103.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$103
What the payments were for
- Food & beverage$14,62498%
- Education$3742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 206 | $3,314 |
| AstraZeneca | 131 | $2,360 |
| Boehringer Ingelheim | 66 | $1,339 |
| Jazz Pharmaceuticals Inc. | 72 | $1,214 |
| Harmony Biosciences LLC | 44 | $893 |
| Insmed, Inc. | 31 | $782 |
| Regeneron Healthcare Solutions, Inc. | 26 | $602 |
| AbbVie(2 entities) | 30 | $588 |
| Mylan Specialty L.p. | 28 | $549 |
| Sanofi | 17 | $425 |
| Grifols USA, LLC | 19 | $369 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $335 |
| Axsome Therapeutics, Inc. | 10 | $237 |
| Merck | 11 | $235 |
| Actelion Pharmaceuticals US, Inc. | 8 | $160 |
| Philips North America LLC | 8 | $150 |
| Astellas Pharma US Inc | 9 | $149 |
| Gilead | 8 | $131 |
| United Therapeutics Corporation | 6 | $121 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $120 |
| Lilly USA, LLC | 5 | $110 |
| Amgen | 5 | $105 |
| Vifor Pharma, Inc. | 3 | $90 |
| Idorsia Pharmaceuticals US Inc | 4 | $81 |
| Inspire Medical Systems, Inc. | 4 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Verona Pharma, Inc. | 3 | $58 |
| Eisai Inc. | 4 | $53 |
| Electromed, Inc. | 3 | $44 |
| Novartis | 2 | $35 |
| Bayer | 2 | $30 |
| Viatris Specialty LLC | 1 | $29 |
| Resmed Corp | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Medtronic | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| 3b Medical, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,998 in reported general payments places this provider in the 70th percentile of 28 sleep medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 48 | $575,602 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 362 | $299,112 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $197,695 |
| OpsumitMacitentan | 15 | $184,847 |
| Ambrisentan | 34 | $154,133 |
| TezspireTezepelumab-Ekko | 24 | $97,660 |
| Dupixent SyringeDupilumab | 24 | $88,281 |
| NucalaMepolizumab | 24 | $81,189 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $75,865 |
| Dupixent PenDupilumab | 13 | $49,857 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $42,780 |
| EliquisApixaban | 50 | $39,766 |
| Spiriva RespimatTiotropium Bromide | 53 | $34,785 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $30,561 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $19,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,339 | $667,046187 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $3,314 | $435,585518 claims |
| Insmed, Inc.Arikayce | $782 | $197,69513 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,360 | $196,422193 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $160 | $184,84715 claims |
| MerckDulera, Belsomra | $235 | $18,53633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 sleep medicine providers in Alabama.
Other sleep medicine in Florence
- James RoyHuntsville$823K
- Michael LedetDaphne$795K
- Gordon WarnerCullman$100K
- James GeyerTuscaloosa$61K
- Ashwin AnanthFoley$57K
- Christopher HopeOpelika$32K
- Bahador TafazoliCullman$26K
- Erin OzgunBirmingham$16K
- Alan ThomasBirmingham$13K
- Darren GannuchHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.